patient_id stringlengths 12 12 | record_id stringlengths 11 11 | cancer_type stringclasses 1 value | histology stringclasses 3 values | stage_at_diagnosis stringclasses 3 values | driver_mutation stringclasses 7 values | pd_l1_tps_percent int64 5 41 | tmb_mutations_per_mb float64 1.5 25 | age_at_diagnosis int64 38 90 | sex stringclasses 2 values | ecog_performance_status int64 0 4 | smoking_pack_years int64 0 111 | primary_tumor_size_cm float64 2 10 | metastatic_sites_count int64 0 11 | first_line_regimen stringclasses 6 values | overall_survival_months float64 4 83 | censored bool 2 classes | msi_status stringclasses 2 values | record_generation_timestamp stringdate 2026-03-15 05:35:56 2026-03-15 05:36:02 | synthetic_source stringclasses 1 value |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
ANODE_563346 | REC_0000901 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 25 | 7.4 | 54 | female | 0 | 77 | 5.5 | 1 | carboplatin + paclitaxel + pembrolizumab | 22.1 | false | MSS | 2026-03-15T05:35:57.062793+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_437752 | REC_0000902 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 26 | 3.8 | 67 | female | 1 | 10 | 7.3 | 1 | osimertinib 80 mg daily | 19 | true | MSS | 2026-03-15T05:35:57.063034+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_817113 | REC_0000903 | Non-small cell lung cancer | Adenocarcinoma | III | ALK fusion | 20 | 15.4 | 69 | female | 1 | 18 | 6.3 | 0 | alectinib 600 mg BID | 42.7 | false | MSI-H | 2026-03-15T05:35:57.063284+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_370856 | REC_0000904 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 26 | 5.8 | 50 | male | 0 | 59 | 4.7 | 2 | carboplatin + paclitaxel + pembrolizumab | 14.7 | false | MSS | 2026-03-15T05:35:57.063524+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_300825 | REC_0000905 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 22 | 6.3 | 63 | female | 0 | 34 | 8 | 4 | carboplatin + paclitaxel + pembrolizumab | 15 | false | MSS | 2026-03-15T05:35:57.063795+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_333548 | REC_0000906 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 19 | 9.9 | 63 | male | 1 | 25 | 3.3 | 6 | entrectinib 600 mg daily | 11.5 | false | MSS | 2026-03-15T05:35:57.064107+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_119351 | REC_0000907 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 24 | 13.2 | 60 | male | 0 | 16 | 8 | 7 | osimertinib 80 mg daily | 18.9 | true | MSI-H | 2026-03-15T05:35:57.064443+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_786353 | REC_0000908 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None (PD-L1 high) | 27 | 3.2 | 75 | female | 0 | 36 | 4.8 | 5 | pembrolizumab 200 mg q3w | 11.2 | false | MSS | 2026-03-15T05:35:57.064742+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_160461 | REC_0000909 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 26 | 9 | 78 | female | 1 | 21 | 6.4 | 7 | sotorasib 960 mg daily | 10.3 | false | MSS | 2026-03-15T05:35:57.065015+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_644025 | REC_0000910 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 27 | 10.8 | 84 | female | 1 | 19 | 6.1 | 5 | osimertinib 80 mg daily | 10.4 | true | MSI-H | 2026-03-15T05:35:57.065265+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_568388 | REC_0000911 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 26 | 13.1 | 72 | female | 0 | 12 | 5 | 6 | alectinib 600 mg BID | 12.3 | true | MSS | 2026-03-15T05:35:57.065641+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_421411 | REC_0000912 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 23 | 10.3 | 63 | female | 0 | 3 | 4 | 7 | entrectinib 600 mg daily | 12.9 | false | MSS | 2026-03-15T05:35:57.065918+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_894655 | REC_0000913 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None (PD-L1 high) | 19 | 9 | 66 | female | 1 | 8 | 8.6 | 7 | pembrolizumab 200 mg q3w | 10 | false | MSS | 2026-03-15T05:35:57.066177+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_937356 | REC_0000914 | Non-small cell lung cancer | Adenocarcinoma | IVA | ROS1 fusion | 19 | 5.8 | 62 | female | 1 | 15 | 5.2 | 2 | entrectinib 600 mg daily | 22.7 | false | MSS | 2026-03-15T05:35:57.066420+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_861712 | REC_0000915 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 20 | 11.9 | 77 | male | 2 | 17 | 5.1 | 3 | osimertinib 80 mg daily | 8.3 | true | MSS | 2026-03-15T05:35:57.066663+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_426849 | REC_0000916 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 21 | 12.5 | 61 | female | 0 | 16 | 5.8 | 5 | alectinib 600 mg BID | 15.1 | true | MSI-H | 2026-03-15T05:35:57.066904+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_593008 | REC_0000917 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 18 | 12.2 | 55 | female | 1 | 12 | 4.9 | 6 | entrectinib 600 mg daily | 4 | true | MSS | 2026-03-15T05:35:57.067148+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_593282 | REC_0000918 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR exon 19 deletion | 27 | 13.5 | 67 | male | 1 | 22 | 7 | 2 | osimertinib 80 mg daily | 19.4 | false | MSS | 2026-03-15T05:35:57.067393+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_877356 | REC_0000919 | Non-small cell lung cancer | Adenocarcinoma | IVA | None (PD-L1 high) | 28 | 13.2 | 78 | female | 3 | 11 | 5.5 | 2 | pembrolizumab 200 mg q3w | 18.3 | false | MSS | 2026-03-15T05:35:57.067638+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_330016 | REC_0000920 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 24 | 15.3 | 74 | male | 2 | 14 | 2.7 | 6 | osimertinib 80 mg daily | 13.2 | false | MSS | 2026-03-15T05:35:57.067879+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_744313 | REC_0000921 | Non-small cell lung cancer | Large cell carcinoma | IVA | None (PD-L1 high) | 25 | 6.7 | 64 | male | 0 | 12 | 5.7 | 2 | pembrolizumab 200 mg q3w | 18.1 | false | MSS | 2026-03-15T05:35:57.068160+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_646722 | REC_0000922 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 21 | 14.1 | 56 | male | 0 | 5 | 5 | 3 | alectinib 600 mg BID | 8.2 | false | MSI-H | 2026-03-15T05:35:57.068420+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_866765 | REC_0000923 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 15 | 17.8 | 69 | female | 0 | 26 | 4.5 | 1 | osimertinib 80 mg daily | 27.6 | false | MSI-H | 2026-03-15T05:35:57.068682+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_269946 | REC_0000924 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 28 | 9 | 72 | male | 1 | 42 | 6.6 | 2 | carboplatin + paclitaxel + pembrolizumab | 17.1 | false | MSS | 2026-03-15T05:35:57.069121+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_436257 | REC_0000925 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 32 | 12.1 | 78 | male | 2 | 20 | 5.2 | 6 | osimertinib 80 mg daily | 9.2 | false | MSS | 2026-03-15T05:35:57.069436+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_383926 | REC_0000926 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 33 | 6.6 | 58 | male | 0 | 20 | 7 | 3 | sotorasib 960 mg daily | 8.2 | true | MSS | 2026-03-15T05:35:57.069720+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_703771 | REC_0000927 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 28 | 9.8 | 67 | male | 1 | 8 | 6.3 | 5 | osimertinib 80 mg daily | 10.1 | true | MSS | 2026-03-15T05:35:57.069997+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_719476 | REC_0000928 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 30 | 13.2 | 62 | female | 1 | 16 | 5.8 | 7 | alectinib 600 mg BID | 6.1 | true | MSS | 2026-03-15T05:35:57.070294+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_801450 | REC_0000929 | Non-small cell lung cancer | Adenocarcinoma | IVB | None (PD-L1 high) | 20 | 6.4 | 59 | male | 1 | 20 | 3.4 | 8 | pembrolizumab 200 mg q3w | 10.4 | true | MSS | 2026-03-15T05:35:57.070558+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_187056 | REC_0000930 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 24 | 15.4 | 64 | male | 1 | 11 | 5.3 | 4 | sotorasib 960 mg daily | 11.3 | true | MSI-H | 2026-03-15T05:35:57.070802+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_875573 | REC_0000931 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 23 | 12.3 | 64 | male | 1 | 23 | 5.1 | 8 | sotorasib 960 mg daily | 19.6 | false | MSI-H | 2026-03-15T05:35:57.071041+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_846536 | REC_0000932 | Non-small cell lung cancer | Large cell carcinoma | IVB | None (PD-L1 high) | 26 | 4.5 | 54 | female | 0 | 24 | 4.9 | 6 | pembrolizumab 200 mg q3w | 11.3 | true | MSS | 2026-03-15T05:35:57.071276+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_846137 | REC_0000933 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR exon 19 deletion | 31 | 10.7 | 62 | male | 0 | 19 | 4.8 | 2 | osimertinib 80 mg daily | 13.3 | true | MSS | 2026-03-15T05:35:57.071520+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_877975 | REC_0000934 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 18 | 1.5 | 66 | male | 0 | 17 | 2.9 | 8 | sotorasib 960 mg daily | 12.3 | false | MSS | 2026-03-15T05:35:57.071759+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_690215 | REC_0000935 | Non-small cell lung cancer | Adenocarcinoma | IVA | None (PD-L1 high) | 17 | 9.2 | 69 | female | 1 | 14 | 5.2 | 2 | pembrolizumab 200 mg q3w | 12.7 | false | MSS | 2026-03-15T05:35:57.071992+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_567007 | REC_0000936 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 37 | 7.3 | 66 | male | 1 | 0 | 4.7 | 3 | entrectinib 600 mg daily | 9 | false | MSS | 2026-03-15T05:35:57.072283+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_452904 | REC_0000937 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 18 | 11.1 | 75 | female | 4 | 15 | 5 | 6 | osimertinib 80 mg daily | 5.2 | false | MSI-H | 2026-03-15T05:35:57.072652+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_768488 | REC_0000938 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 17 | 4.8 | 48 | female | 0 | 19 | 4.8 | 3 | entrectinib 600 mg daily | 11.2 | true | MSS | 2026-03-15T05:35:57.072915+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_625959 | REC_0000939 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 32 | 14.8 | 66 | female | 1 | 20 | 4.8 | 2 | alectinib 600 mg BID | 13.8 | false | MSI-H | 2026-03-15T05:35:57.073157+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_257020 | REC_0000940 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 23 | 8.3 | 64 | female | 1 | 99 | 6 | 6 | carboplatin + paclitaxel + pembrolizumab | 10.9 | true | MSS | 2026-03-15T05:35:57.073395+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_858423 | REC_0000941 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 21 | 7.1 | 70 | male | 1 | 0 | 4.7 | 6 | entrectinib 600 mg daily | 12 | false | MSS | 2026-03-15T05:35:57.073632+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_112004 | REC_0000942 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 22 | 4.5 | 74 | female | 2 | 59 | 6.1 | 5 | carboplatin + paclitaxel + pembrolizumab | 18 | true | MSS | 2026-03-15T05:35:57.073862+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_202336 | REC_0000943 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 24 | 19.2 | 71 | female | 1 | 22 | 6.1 | 9 | sotorasib 960 mg daily | 4 | true | MSS | 2026-03-15T05:35:57.074104+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_284098 | REC_0000944 | Non-small cell lung cancer | Large cell carcinoma | IVB | None (PD-L1 high) | 30 | 6.3 | 70 | female | 1 | 15 | 4.6 | 7 | pembrolizumab 200 mg q3w | 17.7 | false | MSS | 2026-03-15T05:35:57.074340+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_230155 | REC_0000945 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 27 | 11.2 | 71 | female | 3 | 49 | 3.5 | 2 | carboplatin + paclitaxel + pembrolizumab | 11.3 | false | MSS | 2026-03-15T05:35:57.074577+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_325514 | REC_0000946 | Non-small cell lung cancer | Large cell carcinoma | IVB | None (PD-L1 high) | 34 | 5.9 | 72 | female | 2 | 31 | 7.8 | 5 | pembrolizumab 200 mg q3w | 9.5 | false | MSS | 2026-03-15T05:35:57.074813+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_968435 | REC_0000947 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 24 | 11.9 | 71 | female | 1 | 10 | 3.8 | 4 | alectinib 600 mg BID | 12.7 | false | MSI-H | 2026-03-15T05:35:57.075050+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_429778 | REC_0000948 | Non-small cell lung cancer | Adenocarcinoma | IVA | ROS1 fusion | 13 | 8.8 | 72 | male | 1 | 17 | 6 | 2 | entrectinib 600 mg daily | 18.4 | false | MSS | 2026-03-15T05:35:57.075286+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_260059 | REC_0000949 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 18 | 11.2 | 63 | female | 1 | 5 | 3.7 | 8 | osimertinib 80 mg daily | 11.7 | true | MSI-H | 2026-03-15T05:35:57.075525+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_568042 | REC_0000950 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 30 | 10.5 | 71 | female | 2 | 1 | 5.3 | 0 | alectinib 600 mg BID | 13.7 | false | MSS | 2026-03-15T05:35:57.075853+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_119726 | REC_0000951 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 25 | 11.7 | 78 | male | 2 | 23 | 6.5 | 2 | osimertinib 80 mg daily | 16.7 | false | MSS | 2026-03-15T05:35:57.076159+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_705206 | REC_0000952 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 29 | 12 | 70 | female | 3 | 20 | 6 | 7 | alectinib 600 mg BID | 11.4 | false | MSS | 2026-03-15T05:35:57.076436+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_980094 | REC_0000953 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 23 | 11.7 | 83 | female | 3 | 11 | 6.8 | 5 | sotorasib 960 mg daily | 7.7 | false | MSS | 2026-03-15T05:35:57.076752+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_763782 | REC_0000954 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 27 | 6.6 | 65 | female | 0 | 81 | 5.4 | 9 | carboplatin + paclitaxel + pembrolizumab | 17.8 | false | MSS | 2026-03-15T05:35:57.077018+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_472184 | REC_0000955 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 24 | 9.6 | 78 | female | 3 | 21 | 5.6 | 2 | alectinib 600 mg BID | 21.4 | true | MSS | 2026-03-15T05:35:57.077256+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_807795 | REC_0000956 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 28 | 13.2 | 58 | female | 1 | 16 | 6.8 | 5 | alectinib 600 mg BID | 5.7 | true | MSS | 2026-03-15T05:35:57.077499+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_306192 | REC_0000957 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 21 | 16.7 | 54 | male | 0 | 7 | 4.3 | 7 | entrectinib 600 mg daily | 8.1 | false | MSI-H | 2026-03-15T05:35:57.077752+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_166999 | REC_0000958 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 23 | 11.2 | 64 | male | 0 | 19 | 4.1 | 5 | osimertinib 80 mg daily | 13.8 | false | MSS | 2026-03-15T05:35:57.078009+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_963015 | REC_0000959 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None (PD-L1 high) | 32 | 6.8 | 78 | female | 2 | 57 | 3.5 | 6 | pembrolizumab 200 mg q3w | 12.7 | false | MSS | 2026-03-15T05:35:57.078275+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_157942 | REC_0000960 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 22 | 13.7 | 83 | female | 1 | 12 | 6.3 | 5 | sotorasib 960 mg daily | 14.2 | false | MSI-H | 2026-03-15T05:35:57.078560+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_491488 | REC_0000961 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 24 | 2.8 | 67 | female | 0 | 9 | 5.2 | 4 | alectinib 600 mg BID | 10.4 | false | MSS | 2026-03-15T05:35:57.078873+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_179211 | REC_0000962 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 22 | 9.7 | 67 | female | 1 | 17 | 7.2 | 7 | entrectinib 600 mg daily | 8.7 | true | MSS | 2026-03-15T05:35:57.079163+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_715257 | REC_0000963 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None (PD-L1 high) | 24 | 5.8 | 66 | female | 1 | 45 | 7.2 | 7 | pembrolizumab 200 mg q3w | 11.1 | true | MSS | 2026-03-15T05:35:57.079553+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_598885 | REC_0000964 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 29 | 7.6 | 70 | female | 1 | 76 | 5.7 | 2 | carboplatin + paclitaxel + pembrolizumab | 18.3 | true | MSS | 2026-03-15T05:35:57.079832+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_522525 | REC_0000965 | Non-small cell lung cancer | Large cell carcinoma | IVB | None (PD-L1 high) | 24 | 6.4 | 73 | male | 2 | 4 | 5.1 | 8 | pembrolizumab 200 mg q3w | 12.5 | true | MSS | 2026-03-15T05:35:57.080162+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_927589 | REC_0000966 | Non-small cell lung cancer | Adenocarcinoma | IVA | ROS1 fusion | 25 | 10.5 | 62 | male | 0 | 10 | 5.1 | 2 | entrectinib 600 mg daily | 27.5 | true | MSS | 2026-03-15T05:35:57.080438+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_503430 | REC_0000967 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 23 | 11.2 | 63 | male | 1 | 1 | 4.8 | 8 | entrectinib 600 mg daily | 7.8 | true | MSS | 2026-03-15T05:35:57.080682+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_496877 | REC_0000968 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 33 | 15.8 | 65 | male | 0 | 22 | 4.6 | 4 | osimertinib 80 mg daily | 16.7 | false | MSI-H | 2026-03-15T05:35:57.080920+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_503340 | REC_0000969 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 22 | 6.6 | 72 | female | 2 | 23 | 5.4 | 6 | sotorasib 960 mg daily | 7.2 | false | MSS | 2026-03-15T05:35:57.081155+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_934002 | REC_0000970 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 16 | 5.1 | 71 | female | 1 | 17 | 5.6 | 2 | osimertinib 80 mg daily | 11.1 | true | MSS | 2026-03-15T05:35:57.081385+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_826459 | REC_0000971 | Non-small cell lung cancer | Large cell carcinoma | IVA | None (PD-L1 high) | 29 | 6.5 | 75 | female | 1 | 19 | 6.1 | 2 | pembrolizumab 200 mg q3w | 19 | true | MSS | 2026-03-15T05:35:57.081614+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_936645 | REC_0000972 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 20 | 13.4 | 78 | male | 1 | 12 | 5.4 | 5 | alectinib 600 mg BID | 4.2 | true | MSI-H | 2026-03-15T05:35:57.081849+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_569222 | REC_0000973 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 26 | 16.1 | 78 | male | 1 | 10 | 6.2 | 6 | osimertinib 80 mg daily | 8.6 | false | MSS | 2026-03-15T05:35:57.082088+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_558868 | REC_0000974 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 23 | 6.4 | 74 | female | 2 | 61 | 5.5 | 3 | carboplatin + paclitaxel + pembrolizumab | 10.5 | true | MSS | 2026-03-15T05:35:57.082317+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_779307 | REC_0000975 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 24 | 2.5 | 67 | female | 0 | 45 | 3.8 | 1 | carboplatin + paclitaxel + pembrolizumab | 27.5 | false | MSS | 2026-03-15T05:35:57.082553+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_664801 | REC_0000976 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 28 | 5.6 | 61 | male | 0 | 51 | 6.3 | 7 | carboplatin + paclitaxel + pembrolizumab | 15.2 | true | MSS | 2026-03-15T05:35:57.082865+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_973378 | REC_0000977 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 25 | 8.9 | 72 | female | 2 | 44 | 6.8 | 4 | carboplatin + paclitaxel + pembrolizumab | 14.4 | true | MSS | 2026-03-15T05:35:57.083105+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_808461 | REC_0000978 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 24 | 5 | 73 | female | 2 | 37 | 5.4 | 7 | carboplatin + paclitaxel + pembrolizumab | 9.5 | false | MSS | 2026-03-15T05:35:57.083341+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_529239 | REC_0000979 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 22 | 4.8 | 59 | female | 0 | 53 | 4 | 6 | carboplatin + paclitaxel + pembrolizumab | 12.5 | false | MSS | 2026-03-15T05:35:57.083577+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_294789 | REC_0000980 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 22 | 11.3 | 71 | male | 2 | 19 | 3.2 | 3 | sotorasib 960 mg daily | 4 | false | MSS | 2026-03-15T05:35:57.083812+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_608601 | REC_0000981 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 24 | 18.2 | 55 | male | 1 | 16 | 4.4 | 7 | alectinib 600 mg BID | 6.9 | true | MSS | 2026-03-15T05:35:57.084048+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_667665 | REC_0000982 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 24 | 12.6 | 58 | female | 0 | 25 | 5.3 | 2 | sotorasib 960 mg daily | 18.7 | false | MSI-H | 2026-03-15T05:35:57.084321+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_600161 | REC_0000983 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 28 | 10.6 | 61 | male | 1 | 8 | 4.5 | 6 | osimertinib 80 mg daily | 12.7 | false | MSI-H | 2026-03-15T05:35:57.084562+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_697416 | REC_0000984 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 30 | 18.2 | 75 | female | 0 | 16 | 7.8 | 3 | alectinib 600 mg BID | 13.6 | false | MSI-H | 2026-03-15T05:35:57.084802+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_263062 | REC_0000985 | Non-small cell lung cancer | Large cell carcinoma | IVB | None (PD-L1 high) | 28 | 6.1 | 83 | female | 1 | 11 | 6.7 | 6 | pembrolizumab 200 mg q3w | 7 | false | MSS | 2026-03-15T05:35:57.085029+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_421187 | REC_0000986 | Non-small cell lung cancer | Adenocarcinoma | IVA | ROS1 fusion | 27 | 15.3 | 65 | male | 0 | 18 | 6.3 | 2 | entrectinib 600 mg daily | 20.1 | false | MSI-H | 2026-03-15T05:35:57.085264+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_697087 | REC_0000987 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 30 | 10.8 | 66 | female | 0 | 20 | 6.5 | 6 | osimertinib 80 mg daily | 4.4 | false | MSI-H | 2026-03-15T05:35:57.085497+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_739945 | REC_0000988 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 22 | 12.1 | 64 | male | 1 | 12 | 3.4 | 2 | alectinib 600 mg BID | 18.5 | true | MSI-H | 2026-03-15T05:35:57.085733+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_913262 | REC_0000989 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 32 | 15.9 | 60 | female | 1 | 14 | 7.2 | 7 | alectinib 600 mg BID | 6.4 | false | MSI-H | 2026-03-15T05:35:57.086018+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_664050 | REC_0000990 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 26 | 11.2 | 67 | female | 1 | 19 | 6.2 | 4 | osimertinib 80 mg daily | 13.5 | false | MSI-H | 2026-03-15T05:35:57.086253+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_752284 | REC_0000991 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 25 | 5.5 | 85 | female | 1 | 50 | 6.7 | 2 | carboplatin + paclitaxel + pembrolizumab | 10.7 | true | MSS | 2026-03-15T05:35:57.086483+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_255599 | REC_0000992 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR exon 19 deletion | 23 | 11.8 | 64 | female | 1 | 15 | 6.8 | 1 | osimertinib 80 mg daily | 25.4 | false | MSS | 2026-03-15T05:35:57.086722+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_221841 | REC_0000993 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 19 | 8.8 | 67 | female | 0 | 42 | 5.4 | 5 | carboplatin + paclitaxel + pembrolizumab | 13.2 | false | MSS | 2026-03-15T05:35:57.086949+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_417875 | REC_0000994 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 20 | 17.1 | 68 | female | 0 | 20 | 5.6 | 4 | sotorasib 960 mg daily | 7.2 | false | MSI-H | 2026-03-15T05:35:57.087182+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_322442 | REC_0000995 | Non-small cell lung cancer | Adenocarcinoma | IVA | ROS1 fusion | 21 | 15 | 88 | male | 1 | 11 | 6.1 | 1 | entrectinib 600 mg daily | 20.9 | false | MSS | 2026-03-15T05:35:57.087416+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_407970 | REC_0000996 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 28 | 14.8 | 54 | male | 0 | 12 | 4.4 | 6 | entrectinib 600 mg daily | 11.9 | false | MSI-H | 2026-03-15T05:35:57.087649+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_872599 | REC_0000997 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 29 | 6.4 | 62 | male | 0 | 52 | 3.7 | 3 | carboplatin + paclitaxel + pembrolizumab | 16.2 | false | MSS | 2026-03-15T05:35:57.087880+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_606800 | REC_0000998 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 27 | 9.8 | 53 | male | 0 | 5 | 6 | 1 | osimertinib 80 mg daily | 21 | true | MSS | 2026-03-15T05:35:57.088156+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_550060 | REC_0000999 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 21 | 6.9 | 65 | male | 1 | 47 | 7 | 1 | carboplatin + paclitaxel + pembrolizumab | 16.3 | false | MSS | 2026-03-15T05:35:57.088402+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_947221 | REC_0001000 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 24 | 9.4 | 83 | female | 3 | 19 | 5.3 | 7 | osimertinib 80 mg daily | 6.6 | false | MSS | 2026-03-15T05:35:57.088633+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.